Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above

Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. We are conducting a study entitled \"A Randomized, Blinded, Controlled, Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of SYS6052 (Recombinant Herpes Zoster Vaccine (CHO Cell)) Administered to Participants Aged 40 Years and Above\".